These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 2533180

  • 1. Defibrotide and peripheral obliterative arterial disease: preliminary data.
    Arosio E, Pancera P, Zannoni M, Arcaro G, Priante F, Lechi A.
    Int J Clin Pharmacol Ther Toxicol; 1989 Nov; 27(11):526-9. PubMed ID: 2533180
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease.
    Strano A, Fareed J, Sabbá C, Albano O, Allegra C, Carlizza A, Binaghi F, Fronteddu F, Del Guercio R, Arpaia MR.
    Semin Thromb Hemost; 1991 Nov; 17 Suppl 2():228-34. PubMed ID: 1948094
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
    Arosio E, Sardina M, Prior M, De Marchi S, Zannoni M, Bianchini C.
    Eur Rev Med Pharmacol Sci; 1998 Nov; 2(2):53-9. PubMed ID: 10229559
    [Abstract] [Full Text] [Related]

  • 10. Effects of defibrotide on peripheral obliterative vascular diseases.
    Ulutin ON, Ilhan-Berkel N, Tunali H, Ozer M, Balkuv-Ulutin S, Onsel C, Urgancioğlu I.
    Haemostasis; 1986 Nov; 16 Suppl 1():59-62. PubMed ID: 3754837
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease.
    Allegra C, Antignani PL, Schachter I, Koverech A, Messano M, Virmani A.
    Ann Vasc Surg; 2008 Nov; 22(4):552-8. PubMed ID: 18502605
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Therapy of deep venous thrombosis with defibrotide. Pilot study].
    Sammarco M, Garofalo M, Nazzari M.
    Minerva Med; 1988 Jun; 79(6):495-7. PubMed ID: 2967927
    [No Abstract] [Full Text] [Related]

  • 15. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
    Qureshi A, Marshall L, Lancaster D.
    Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Prostacyclin and pentoxifylline in the treatment of patients with inoperable occlusions of the peripheral arteries of the lower extremities].
    Maksimović ZV.
    Srp Arh Celok Lek; 1999 Apr; 127(7-8):249-53. PubMed ID: 10624398
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical evaluation of short-term defibrotide treatment of patients with atherosclerosis obliterans of the lower limbs.
    Avellone G, Mandalà V, Pinto A, Martino A, Strano A.
    Haemostasis; 1986 Apr; 16 Suppl 1():55-8. PubMed ID: 2423422
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.